LifeMine Therapeutics
Cambridge, Massachusetts, United States · Biopharma, Biotechnology, Healthcare
LifeMine Therapeutics Inc. is a clinical-stage biopharmaceutical company pioneering Top-Down Drug Discovery™. The company leverages digital genomic search technology from fungi to source next-generation precision medicines. They focus on developing therapies for transplantation and immunology.
Key facts
- Headquarters
- Cambridge, Massachusetts, United States
- Employees
- 51
- Industries
- Biopharma, Biotechnology, Healthcare
- Status
- Private
- Website
- lifeminetx.com
- Company page
Recent activity at LifeMine Therapeutics
- : LifeMine secures $263 million in funding for its new drug development efforts, including a previously undisclosed $75 million Series D round. This capital aims to advance therapies for organ transplant patients and autoimmune conditions.
- : LifeMine Therapeutics Inc. raises $263 million in a funding round to accelerate the clinical development of LIFE-001 and advance its pipeline.
- : LifeMine Therapeutics Announces $50 Million Series B Financing
- : LifeMine Therapeutics, Inc.
- : LifeMine Therapeutics, Inc.
- : LifeMine Therapeutics, Inc.
LifeMine Therapeutics funding history
| Date | Round | Amount |
|---|---|---|
| Aug 2026 | Venture | $263.0M |
| Jan 2021 | Series B | $50.0M |
| Sep 2017 | Venture | $25.1M |
| Oct 2016 | Venture | $5.0M |
Leadership
- Richard Klausner, Director
- Wei Li, Director
- Yanling Cao, Director
- Krishna Yeshwant, Director
- Gregory Verdine, Executive Officer, Director
- Edward Hu, Director
- Jim Tananbaum, Director
- Hingge Hsu, Executive Officer, Director
Verified email and direct lines for LifeMine Therapeutics’s decision-makers are on Fundz. See plans — or book a 15-minute walkthrough.
Employee benefit plans
LifeMine Therapeutics files 2 employee benefit plans with the U.S. Department of Labor, including a retirement plan. The next plan year renews in Dec 2026.
LifeMine Therapeutics in the news
- LifeMine Raises $263 Million to Accelerate the Clinical Development of LIFE-001, a Structurally and Mechanistically Novel Calcineurin Activation Inhibitor Designed to Transform Organ Transplantation - Yahoo Finance (Aug 06, 2026)
- Life-Saving Drugs Hiding in Plain Sight: LifeMine Therapeutics CEO Greg Verdine, Live at NYSE - IPO Edge (Feb 18, 2025)
- LifeMine Therapeutics Announces $175 Million Series C Financing - Business Wire (Mar 23, 2022)
- LifeMine Therapeutics Announces $50 Million Series B Financing - Business Wire (Jan 07, 2021)
Companies similar to LifeMine Therapeutics
- OnKure Therapeutics · Biopharma, Biotechnology, Healthcare, Therapeutics
- Terns Pharmaceuticals · Biopharma, Biotechnology, Healthcare, Therapeutics
- BioLineRx Ltd · Biopharma, Biotechnology, Healthcare, Therapeutics
- Tempest Therapeutics · Biopharma, Biotechnology, Healthcare, Therapeutics
- Retension Pharmaceuticals · Biopharma, Biotechnology, Healthcare, Therapeutics
About LifeMine Therapeutics: questions and answers
What does LifeMine Therapeutics do?
LifeMine Therapeutics Inc. is a clinical-stage biopharmaceutical company pioneering Top-Down Drug Discovery™. The company leverages digital genomic search technology from fungi to source next-generation precision medicines. They focus on developing therapies for transplantation and immunology.
Where is LifeMine Therapeutics headquartered?
LifeMine Therapeutics is headquartered in Cambridge, Massachusetts, United States.
How many employees does LifeMine Therapeutics have?
LifeMine Therapeutics has about 51 employees.
Has LifeMine Therapeutics raised funding?
Yes. Fundz has recorded 4 funding events for LifeMine Therapeutics. The most recent, $263.0M, was in Aug 2026.
What is the latest news on LifeMine Therapeutics?
On Aug 06, 2026, LifeMine secures $263 million in funding for its new drug development efforts, including a previously undisclosed $75 million Series D round. This capital aims to advance therapies for organ transplant patients and autoimmune conditions.
Source: Fundz records from SEC filings, press releases and company announcements. How Fundz measures data accuracy